- Home
- EDD vs AUTL Comparison
EDD vs AUTL Comparison
Compare EDD & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EDD | AUTL |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.7M | 431.2M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | EDD | AUTL |
|---|---|---|
| Price | $5.51 | $1.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 450.0K | ★ 1.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.52% | N/A |
| EPS Growth | N/A | ★ 28.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | N/A | $670.78 |
| Revenue Next Year | N/A | $80.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $4.28 | $1.11 |
| 52 Week High | $6.18 | $2.70 |
Technical Indicators
Market Signals| Indicator | EDD | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 24.03 | 44.77 |
| Support Level | $5.45 | $1.27 |
| Resistance Level | $5.69 | $1.52 |
| Average True Range (ATR) | 0.09 | 0.12 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 4.29 | 18.27 |
Price Performance
Historical ComparisonAbout EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.